Flywheel Private Wealth LLC Makes New $340,000 Investment in Amgen Inc. (NASDAQ:AMGN)

Flywheel Private Wealth LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 1,305 shares of the medical research company's stock, valued at approximately $340,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Talbot Financial LLC raised its position in shares of Amgen by 5.6% in the fourth quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock valued at $11,153,000 after purchasing an additional 2,274 shares during the period. Swiss National Bank increased its holdings in Amgen by 0.3% during the 3rd quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company's stock worth $513,033,000 after acquiring an additional 5,500 shares during the period. Asset Advisors Investment Management LLC increased its holdings in Amgen by 9.0% during the 3rd quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock worth $11,578,000 after acquiring an additional 2,954 shares during the period. Principal Financial Group Inc. increased its holdings in Amgen by 6.0% during the 3rd quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock worth $204,659,000 after acquiring an additional 35,785 shares during the period. Finally, First Horizon Advisors Inc. increased its holdings in Amgen by 3.2% during the 3rd quarter. First Horizon Advisors Inc. now owns 60,769 shares of the medical research company's stock worth $19,581,000 after acquiring an additional 1,872 shares during the period. Institutional investors own 76.50% of the company's stock.

Amgen Trading Up 0.2 %

AMGN traded up $0.49 during trading on Thursday, hitting $269.43. 2,684,349 shares of the stock traded hands, compared to its average volume of 3,105,385. The firm has a market capitalization of $144.83 billion, a P/E ratio of 34.50, a price-to-earnings-growth ratio of 2.68 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The firm has a 50-day moving average of $276.06 and a 200 day moving average of $307.76. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating the consensus estimate of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analysts' expectations of $8.50 billion. During the same quarter in the prior year, the company posted $4.96 EPS. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 19.57 EPS for the current year.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.53%. Amgen's dividend payout ratio is 115.24%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on AMGN shares. Citigroup decreased their target price on shares of Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. Truist Financial decreased their price target on shares of Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a report on Wednesday, January 8th. StockNews.com lowered shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Bank of America reissued an "underperform" rating and issued a $256.00 price target on shares of Amgen in a report on Tuesday, December 10th. Finally, William Blair reissued an "outperform" rating on shares of Amgen in a report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Amgen has a consensus rating of "Hold" and a consensus target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.